Post-operative Complications Clinical Trial
Official title:
Impact of Graft Steatosis on Post-operative Complications After Liver Transplantation
1. Clinical impact of graft steatosis on postoperative complications after OLT.
2. Recommendations to improve outcomes after transplantation of steatotic livers and
increase donor pool.
Introduction Solid organ transplantation has become the standard of care for selected
patients with end-stage organ dysfunction. With improved surgical techniques, more effective
immunosuppressive therapies, and better anti-infective medications, outcomes after solid
organ transplantation have improved over the last several years.
The excellent survival rates reported after orthotopic liver transplantation (OLT) have
increased the demand for liver transplants and have enhanced the disparity between the
number of available donor organs and the need for such organs.
The lack of available organs for liver transplantation (LT) associated with the increased
death rates among patients on most waiting lists for LT has triggered the use of so-called
extended criteria donor (ECD) grafts, previously called ''suboptimal grafts''. Among the
wide range of these ECD livers, hepatic steatosis is one of the most frequent disorders,
which is mostly related to an increasing prevalence of non-alcoholic fatty liver disease
(NAFLD).
Non-alcoholic fatty liver disease (NAFLD) is increasingly significant in healthy individuals
for its high worldwide prevalence, an association with the metabolic syndrome such as
insulin resistance, diabetes, dyslipidemia and obesity, and an association with
liver-related morbidity and mortality.
Clinical evaluation and current imaging modalities, and serological and laboratory tests can
be strongly suggestive of the presence of hepatic steatosis, but none of these is capable of
distinguishing steatohepatitis (SH) from uncomplicated steatosis; likewise, these
evaluations can generally detect advanced liver disease (e.g. portal hypertension), but none
can truly assess the degree of liver necroinflammatory injury, lesser stages of fibrosis and
architectural remodeling. Liver biopsy evaluation, therefore, remains the 'gold standard' to
unequivocally diagnose SH and to document the severity of hepatic injury and fibrosis.
Steatosis is assessed according to the pattern and the amount of fatty infiltration in
hepatic tissue sections. Traditionally, fatty accumulation has been classified
morphologically as macrovesicular or microvesicular. Macrovesicular steatosis is
characterized by a single, bulky fat vacuole in the hepatocyte that displaces the nucleus to
the edge of the cell. The less conspicuous microvesicular steatosis, usually related to
toxins or metabolic disorders, is characterized by accumulation of tiny lipid vesicles in
the cytoplasm of hepatocytes without nuclear dislocation. Current quantification and grading
of liver steatosis originates from studies performed in the early 1990s, when steatosis was
classified as mild, moderate, or severe if, less than 30%, 30-60%, or more than 60% of
hepatocytes, respectively, display fatty infiltrations.
Although usually benign, fatty liver may associate with serious injury, with inflammation
and hepatocyte necro-apoptosis, non-alcoholic steatohepatitis (NASH), in 20-30% of subjects.
Those patients are at risk of developing fibrosis, one fifth progressing to liver cirrhosis.
It is apparently more slowly progressive than other chronic liver diseases, such as alcohol
or viral-induced disease. Moreover, the problem of hepatocytes being fatty, overcomes the
liver itself, as it increases the risk for cardiovascular disease and death and duplicates
the risk for type 2 diabetes mellitus (T2DM), independently of the severity of liver injury.
Severe fatty livers are more susceptible to warm and cold ischemia reperfusion injury than
normal ones. The type of damage is not through the pathway of cellular apoptosis, but
necrosis.
The use of steatotic grafts for orthotopic liver transplantation (OLT) is associated with a
high rate of primary graft dysfunction and decreased graft and patient survival particularly
with macro-steatosis.
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02571400 -
Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study
|
N/A | |
Completed |
NCT02238561 -
The Cost in Oxygen of Surgical Trauma
|
N/A | |
Not yet recruiting |
NCT02096640 -
Postoperative Inflammation and Recovery After Tracheostomy
|
N/A | |
Suspended |
NCT01998815 -
Role and Mechanisms of Obesity Surgery
|
||
Completed |
NCT02438293 -
'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
|
||
Unknown status |
NCT00665587 -
AMAZING PRAGUE (PRAGUE-12)
|
N/A | |
Enrolling by invitation |
NCT00606372 -
On-Pump vs. Off-Pump CABG in High-Risk Patients (EuroSCORE 6+)
|
N/A | |
Recruiting |
NCT03643718 -
Web-based International Register of Emergency Surgery and Trauma
|
||
Completed |
NCT01801813 -
Risk Factors of Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery (Cranioscore).
|
N/A | |
Completed |
NCT01137084 -
Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
|
N/A | |
Recruiting |
NCT04892901 -
Erector Spinae Plane Block in Uniportal VATS
|
||
Completed |
NCT03551899 -
Intra-operative Ventilatory Management & Post-operative Pulmonary Complications
|
||
Completed |
NCT01450631 -
The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions
|
N/A |